MAWAG
IBRX icon

Mid-American Wealth Advisory Group’s ImmunityBio IBRX Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-465
Closed -$1.23K – 163
2025
Q2 		$1.23K Buy
+465
New +$1.25K ﹤0.01% 283

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Mid-American Wealth Advisory Group's IBRX Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 465 shares — an estimated $1.23K sold.

Mid-American Wealth Advisory Group first reported a position in IBRX in Q2 2025 and held it in 1 quarter. The position peaked at $1.23K in Q2 2025. 263 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 465 ImmunityBio shares in Q3 2025, an estimated $1.23K.
  • Mid-American Wealth Advisory Group first reported a position in ImmunityBio in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's ImmunityBio position peaked at $1.23K in Q2 2025.
  • 263 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.